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INTRODUCTION
Epithelial	ovarian	cancer	is	the	leading	cause	of	death	from	
malignant	gynecologic	neoplasms	in	the	developed	world.	
Spread	of	the	disease	is	most	frequently	through	transcoelo-
mic	dissemination	by	exfoliation	of	cells	along	the	surface	of	
the	peritoneal	cavity,	and	most	residual	tumors	or	recurrent	
ovarian	cancers	are	located	in	the	pelvic	cavity.	
Until	now,	the	standard	treatment	has	included	primary	
staging	or	cytoreductive	surgery	followed	by	systemic	che-
motherapy.	Due	to	the	known	spread	pattern	of	the	disease,	
intraperitoneal	(IP)	chemotherapy	may	be	considered	as	an	
additional	treatment	modality	after	cytoreductive	surgery	to	
facilitate	higher	tumor	penetration	and	concentration	of	the	
cytotoxic	drug	in	the	peritoneal	cavity.	Based	on	the	results	
of	recent	randomized	phase	III	trials,	a	combination	of	intra-
venous	(IV)	and	IP	administration	of	chemotherapy	shows	a	
significant	survival	benefit	among	women	with	optimally	deb-
Original Article
Intraoperative intraperitoneal chemotherapy with 
cisplatin in epithelial ovarian cancer
Myung Joo Kim*, Yong Wook Jung*, Seok Ju Seong, Bo Sung Yoon, Mi La Kim, Won Deok Joo, Tae Jong Song
Department of Obstetrics and Gynecology, CHA Gangnam Medical Center, CHA University School of Medicine, Seoul, Korea
See accompanying editorial on page 75.
Received Nov 28, 2011, Revised Jan 21, 2012, Accepted Feb 1, 2012
*Both authors contributed equally.
Correspondence to Seok Ju Seong
Department of Obstetrics and Gynecology, CHA Gangnam Medical Center, 
CHA University School of Medicine, Nonhyeon-ro 566, Gangnam-gu, Seoul 
135-913, Korea. Tel: 82-2-3468-3673, Fax: 82-2-3468-2638, E-mail: sjseong@
cha.ac.kr
pISSN 2005-0380 
eISSN 2005-0399
Copyright © 2012. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology 
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License 
(http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and 
reproduction in any medium, provided the original work is properly cited.
www.ejgo.org
Objective:	To	assess	retrospectively	the	feasibility	of	intraoperative	intraperitoneal	(IP)	chemotherapy	with	cisplatin	in	epithelial	
ovarian	cancer.	
Methods: IP	chemotherapy	during	optimal	staging	surgery	was	performed	in	10	patients	who	were	diagnosed	with	primary	
epithelial	ovarian	cancers	between	April	2008	and	February	2011.	Cisplatin	(70	mg/m
2	in	1	L	normal	saline	solution)	was	
administered	in	the	abdominal	cavity	for	24	hours	postoperatively	and	then	adjuvant	chemotherapy	was	started	2-4	weeks	
after	surgery.	Perioperative	toxicity	of	the	combined	treatment	was	evaluated	until	the	initiation	of	postoperative	adjuvant	
chemotherapy.
Results:	A	total	of	23	adverse	events	were	observed	in	9	of	10	patients	(grade	1,	7;	grade	2,	13;	grade	3,	3;	grade	4,	0).	In	
descending	order	of	frequency,	adverse	events	affected	the	gastrointestinal	system	(n=14),	hematologic	system	(n=6),	
pulmonary	system	(n=2),	and	genito-urinary	system	(n=1).	The	adverse	events	did	not	affect	adjuvant	systemic	chemotherapy	
schedules.	One	patient	experienced	disease	recurrence	in	the	liver	16	months	after	surgery.	The	remaining	9	patients	have	been	
well	controlled	by	chemotherapy	and/or	observation	during	the	follow-up	period	of	4	to	39	months	after	surgery.	
Conclusion:	Intraoperative	IP	chemotherapy	with	cisplatin	during	surgical	procedures	is	considered	feasible	for	the	treatment	
of	primary	epithelial	ovarian	cancer.	Further	studies,	including	long-term,	prospective	and	comparative	trials,	are	needed	to	
validate	the	efficacy	of	this	combined	therapy.
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ulked	epithelial	ovarian	cancer,	compared	to	IV	administration	
alone	[1-4].
The	use	of	IP	chemotherapy	at	the	time	of	surgery	and/
or	in	the	immediate	postoperative	period	facilitates	uniform	
drug	delivery	and	may	avoid	some	of	the	complications	of	
prolonged	peritoneal	access	[3].	The	immediate	intraopera-
tive	hyperthermic	intraperitoneal	chemotherapy	(HIPEC)	
procedure	has	the	potential	to	maximize	the	strengths	and	
minimize	the	weaknesses	associated	with	IP	chemotherapy,	
including	catheter-related	complications.	The	addition	of	heat	
augments	the	cytotoxic	effect	of	many	chemotherapeutic	
agents	through	pharmacokinetic	mechanisms	such	as	in-
creased	cell	membrane	permeability,	improved	membrane	
transport,	destructive	capacity	by	elevated	lysosomal	enzyme	
activity	in	malignant	cells,	and	temperature-dependent	in-
creases	in	drug	action	[5,6].	A	systematic	review	of	the	avail-
able	data	of	phase	II	trials	of	HIPEC	suggested	promising	over-
all	survival	outcomes	(range,	22	to	54	months)	[3].	However,	
HIPEC	requires	additional	equipment	such	as	heater,	pumps,	
etc.,	lengthens	the	operation	time	by	at	least	1-2	hours,	and	
is	highly	expensive.	Therefore,	we	introduced	intraoperative	
IP	chemotherapy	immediately	after	completion	of	the	cytore-
ductive	surgery	in	treating	epithelial	ovarian	cancer.	This	pilot	
study	was	performed	to	assess	the	feasibility	of	intraoperative	
IP	chemotherapy	with	cisplatin	in	epithelial	ovarian	cancer.	
MATERIALS AND METHODS
IP	chemotherapy	during	surgery	in	patients	who	were	diag-
nosed	with	primary	epithelial	ovarian	cancers	and	underwent	
an	optimal	staging	procedure	was	performed	at	CHA	Gang-
nam	Medical	Center,	CHA	University	between	April	2008	and	
February	2011.	Eligibility	criteria	for	inclusion	in	the	study	were	
as	follows:	patients	diagnosed	with	primary	epithelial	ovarian	
cancer;	FIGO	stages	IC	to	IV;	Eastern	Cooperative	Oncology	
Group	(ECOG)	performance	status	0	to	1;	underwent	compre-
hensive	staging	procedures;	and	achieved	optimal	cytoreduc-
tive	surgery.	
All	patients	had	a	preoperative	physical	examination,	trans-
vaginal	ultrasonography	and	an	abdomino-pelvic	CT.	Patients	
with	good	performance	status	were	considered	for	surgery.	
Perioperative	antibiotics	and	postoperative	thromboembolic	
prophylaxis	with	low	molecular-weight	heparin	and	pressure	
stockings	were	routinely	used.
Optimal	cytoreductive	surgery	was	defined	as	the	absence	
of	gross	tumor	lesion	after	the	procedures.	To	eradicate	all	
macroscopic	tumors,	standard	staging	procedures	including	
hysterectomy,	salpingo-oophorectomy,	omentectomy	and	
lymph	node	dissection	or	debulking	surgery	such	as	mass	
excision	were	performed.	The	largest	dimension	of	the	largest	
residual	tumor	after	surgery	was	agreed	on	among	the	at-
tending	surgeons.	
IP	chemotherapy	was	administered	through	open	or	lapa-
roscopic	procedures	according	to	the	surgical	approach.	A	
cisplatin	dose	of	70	mg/m
2	in	1	L	normal	saline	solution	was	
administered	into	the	abdominal	cavity.	Two	closed	drains	
(Barovac;	Sewoon	Medical	Co.,	Cheonan,	Korea)	remained	in	
the	pelvic	cavity.	Twenty-four	hours	after	the	operation,	intra-
abdominal	drain	locks	were	released	to	remove	the	cytotoxic	
agent.
Prophylactic	antibiotics	were	administered	intravenously	and	
intramuscularly	for	7	days	postoperatively	(third	generation	
cephalosporin,	aminoglycoside,	metronidazole)	followed	by	
prescription	of	oral	antibiotics.	Intravenous	Patient-Controlled	
Analgesia	(drug	mixture	of	Fentanyl	400	µg	and	Ketorolac	tro-
methamine	120	mg	in	5%	dextrous	water	78	mL,	continuously	
infused	at	2	mL/hour	via	infusion	pump	[WalkMed	Infusion,	
Englewood,	CO,	USA]	for	2	days)	was	used	to	relieve	postop-
erative	pain.	Patients	were	allowed	sips	of	water	after	passing	
gas	and	a	clear	liquid	diet	was	offered	as	the	first	meal	on	
postoperative	day	3.	The	next	meal	was	a	soft	diet	and	then	
patients	were	offered	a	general	diet.	
The	perioperative	toxicity	was	evaluated	during	the	period	
from	the	end	of	this	combined	treatment	to	the	initiation	of	
postoperative	adjuvant	chemotherapy.	The	database	included	
adverse	events	assigned	by	organ	system	as	described	by	Yan	
et	al.	[7],	Washington	Cancer	Institute.	For	each	adverse	event,	
a	grade	1	to	4	score	with	increasing	severity	was	assigned	
as	follows:	a	grade	1	adverse	event	required	no	treatment;	a	
grade	2	adverse	event	required	medical	treatment;	a	grade	3	
adverse	event	was	potentially	serious,	but	resolved	conserva-
tively	with	invasive	intervention,	such	as	a	CT	or	ultrasound-
guided	diagnostic	or	therapeutic	procedure;	and	a	grade	4	
adverse	event	required	a	definitive	urgent	intervention	such	
as	reoperation	or	return	to	the	intensive	care	unit.	All	data	
were	collected	retrospectively	through	chart	review.	The	In-
stitutional	Review	Board	of	CHA	Gangnam	Medical	Center	ap-
proved	this	study.	
All	statistical	calculation	and	analysis	was	done	by	using	
SPSS	ver.	17.0	(SPSS	Inc.,	Chicago,	IL,	USA).
RESULTS
This	study	included	10	consecutive	patients	with	primary	
ovarian	cancer	who	underwent	IP	chemotherapy	immediately	
after	optimal	cytoreductive	surgery.	All	procedures	were	per-Intraoperative IP chemotherapy in ovarian cancer
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formed	by	the	same	surgeon	(SJS).	Table	1	demonstrates	the	
patient	characteristics.	Median	age	was	41	years	(range,	28	to	
52	years),	and	median	body	mass	index	was	21.6	(range,	17.3	
to	27.3).	One	patient	(10%)	had	coexisting	hypertension	that	
was	well	controlled	and	did	not	pose	a	marked	impairment	
for	the	combined	treatment.	No	patient	received	neoadjuvant	
chemotherapy.	The	baseline	median	CA-125	level	was	51.4	U/
mL	(range,	10.0	to	12,860.0	U/mL).	The	stages	of	ovarian	car-
cinoma	were	IC	(n=6),	IIIB	(n=1),	and	IIIC	(n=3).	The	histology	
of	ovarian	carcinoma	was	as	follows:	serous	carcinoma	(n=4),	
mucinous	carcinoma	(n=2),	endometrioid	carcinoma	(n=2),	
and	clear	cell	carcinoma	(n=2).	
1. Treatment-related outcomes 
Table	2	shows	the	operative	procedures	for	ovarian	cancer.	
All	10	patients	underwent	salpingo-oophorectomy,	pelvic	
lymph	node	dissection,	and	omentectomy;	6	patients	had	sur-
gery	by	laparotomy	and	4	patients	by	laparoscopy.
Total	abdominal	or	laparoscopic	hysterectomies	were	per-
formed	in	7	patients	(abdominal	6	and	laparoscopic	1,	respec-
tively).	Three	patients	who	had	no	children	did	not	undergo	
hysterectomy	to	preserve	fertility.	Five	patients,	including	the	
3	who	did	not	have	hysterectomies,	underwent	unilateral	
salpingo-oophorectomy.	One	patient	among	these	5	patients	
underwent	unilateral	salpingo-oophorectomy	because	she	
had	undergone	contralateral	adnexectomy	previously.	The	
other	5	patients	underwent	bilateral	salpingo-oophorectomy	
during	the	study	period.	
Nine	patients	underwent	paraaortic	lymph	node	dissection.	
Eight	patients	underwent	appendectomy	while	1	patient	had	
undergone	appendectomy	previously.	One	patient	under-
went	resection	of	bladder	peritoneum	and	rectal	serosa	for	
suspicious	small	cancerous	masses	in	those	areas.	
The	median	duration	of	surgical	procedures	with	IP	che-
motherapy	was	340	minutes	(range,	210	to	420	minutes).	
The	median	blood	loss	was	500	mL	(range,	200	to	2,000	mL)	
(Table	3).	The	blood	loss	of	2	patients	exceeded	1,000	mL	and	
6	patients,	including	these,	were	given	transfusion	intraopera-
tively	and/or	postoperatively.	The	median	interval	to	passage	
of	flatus	was	2	days	(range,	1	to	3	days).	A	Foley	catheter	was	
removed	3	days	after	surgery	(range,	2	to	5	days).	The	median	
length	of	hospital	stay	was	16	days	(range,	6	to	23	days).	
Postoperative	chemotherapy	was	started	in	days	12-26	post-
operatively.	Nine	patients	received	intravenous	chemothera-
py:	8	with	paclitaxel	(175	mg/m
2)	and	carboplatin	(AUC	5)	and	
1	with	cisplatin	(50	mg/m
2),	doxorubicin	(50	mg),	and	cyclo-
phosphamide	(200	mg).	Only	1	patient	who	was	diagnosed	as	
Table 1. Characteristics of patients (n=10)
Variables Values
Age (yr)*  41 (28-52)
Body mass index*   21.6 (17.3-27.3)
Comorbidity at the time of surgery   1
Neoadjuvant chemotherapy  0
CA-125 (U/mL)*  51.4 (10.0-12,860.0)
Stage  
   IC 6
   IIIB 1
   IIIC  3
Histology  
   Serous  4
   Mucinous  2
   Endometrioid  2
   Clear cell  2
Grade  
   1 5
   2  2
   3 3
*Values are presented as median (range). 
Table 2. Extent of surgical procedures (n=10)
Variables No.
Hysterectomy  7
Salpingo-oophorectomy 10
   Unilateral 5
   Bilateral 5
Pelvic lymph node dissection  10
Paraaortic lymph node dissection  9
Omentectomy  10
Appendectomy 8
Bladder peritoneum resection 1
Rectal serosa resection 1
Table 3. Surgical outcomes
Variables  Values
Duration of surgery (min)* 340 (210-420)
Intraoperative blood loss (mL)* 500 (200-2,000)
   ≤1,000  8
   >1,000  2
Transfusion  6
Length of hospital day*  16 (6-23)
Chemotherapy day after surgery*  18 (12-26)
*Values are presented as median (range). Myung Joo Kim, et al.
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stage	IC	and	had	no	evidence	of	residual	disease	refused	ad-
ditional	systemic	chemotherapy	and	was	followed	up	closely	
without	treatment.	
Among	patients	who	received	postoperative	chemotherapy,	
5	received	the	planned	6	cycles	of	paclitaxel	and	carboplatin	
regimen.	One	patient	with	a	stage	III	tumor	received	5	cycles	
of	belotecan	(a	camptothecin	analogue)	as	second-line	che-
motherapy	because	of	the	disease	progression	after	6	cycles	
of	paclitaxel	and	carboplatin.	This	patient	received	another	6	
cycles	of	docetaxel	and	cisplatin	as	third-line	treatment	due	to	
liver	metastasis	which	occurred	16	months	after	surgery.	One	
patient	received	only	3	cycles	of	paclitaxel	and	carboplatin	
because	image	study	and	CA-125	were	continuously	within	
normal	ranges.	One	patient	only	recently	finished	3	cycles	
of	adjuvant	chemotherapy	and	is	scheduled	to	complete	6	
cycles.	
One	patient	with	cisplatin,	doxorubicin,	and	cyclophos-
phamide	chemotherapy	has	finished	6	cycles	and	the	image	
study	and	CA-125	were	continuously	within	normal	ranges.	
2. Morbidity by organ systems 
Table	4	demonstrates	the	incidence	of	perioperative	adverse	
events	by	4	organ	systems.	A	total	of	23	adverse	events	of	
grade	1	to	3	were	observed	in	9	of	10	patients.	In	descend-
ing	order	of	frequency,	adverse	events	affected	the	gastro-
intestinal	system	(14	events	in	9	patients),	hematologic	sys-
tem	(6	events	in	6	patients),	pulmonary	system	(2	events	in	2	
patients),	and	genito-urinary	system	(1	event).	Mortality	was	
not	observed	in	the	study.	Fig.	1	shows	the	incidence	of	each	
adverse	event.	
The	median	number	of	adverse	events	was	2	(range,	0	to	
5)	in	patients	who	had	IP	chemotherapy	after	surgery.	Four	
patients	experienced	7	grade	1	adverse	events	that	were	self-
Table 4. Incidence of perioperative adverse events by organ system and grade
Organ system Incidence
Adverse event
Grade 1 Grade 2 Grade 3 Grade 4
Gastrointestinal (n=14) 5 9
   Nausea/vomiting  9 2 7 - -
   Ileus  2 2 - - -
   Diarrhea  1 - 1 - -
   AST/ALT elevatioin 2 1 1 - -
Hematologic (n=6) 3 3
   Anemia  6 - 3 3 -
Pulmonary (n=2) 1 1
   Pleural effusion  2 1 1 - -
Genitourinary (n=1) 1
   Hypercreatinemia  1 1 - - -
Total  23 7 (30.4%) 13 (56.5%) 3 (13.0%) -
Percentage indicates incidence of each grade among total adverse events. 
AST/ALT, aspartate aminotransferase/alanine aminotransferase.
Fig. 1. Incidence (%) of 23 grade (G) 1 to 3 adverse events in patients 
with primary epithelial ovarian cancer who underwent cytoreductive 
surgery followed by intraoperative intraperitoneal (IP) chemotherapy. 
Nine of 10 patients experienced more than one adverse event of 
which 87% were grade 1 or 2. AST/ALT, aspartate aminotransferase/
alanine aminotransferase.Intraoperative IP chemotherapy in ovarian cancer
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limiting.	In	descending	order	of	frequency,	these	grade	1	adverse	
events	included	transient	nausea	or	vomiting,	which	was	
controlled	by	discontinuation	of	patient-controlled	anesthe-
sia	(n=2);	ileus	with	minimal	symptoms	controlled	by	taking	
nothing	by	mouth	and	hydration	(n=2);	high	serum	creatinine	
(n=1);	aspartate	aminotransferase/alanine	aminotransferase	
(AST/ALT)	elevation	without	clinical	significance	and	normal-
ized	without	medication	(n=1);	and	asymptomatic	pleural	
effusion	(n=1).	Nine	patients	experienced	13	grade	2	adverse	
events,	which	required	medical	treatment	for	resolution.	In	
descending	order	of	frequency,	these	grade	2	adverse	events	
included	nausea	or	vomiting	requiring	antiemetics	(n=7);	ane-
mia	requiring	transfusion	of	≤4	U	(n=3);	tolerable	diarrhea,	but	
≥2	days’	duration	(n=1);	AST/ALT	elevation	requiring	hepa-
totonics	(n=1);	and	pleural	effusion	requiring	diuretics	(n=1).	
Three	patients	experienced	3	grade	3	adverse	events	which	
required	invasive	medical	intervention	for	resolution.	In	this	
study,	grade	3	adverse	events	included	only	anemia	requir-
ing	transfusion	of	>4	U	(n=3).	There	was	no	grade	4	adverse	
event.
DISCUSSION
The	objective	of	this	pilot	study	was	to	investigate	the	fea-
sibility	of	intraoperative	IP	chemotherapy	immediately	after	
optimal	cytoreductive	surgery	in	primary	epithelial	ovarian	
cancer	patients,	with	a	focus	on	associated	postoperative	
morbidity	and	toxicity.	The	majority	of	events	(87%,	20	of	23	
events;	9	of	10	patients)	were	grades	1	or	2,	which	were	self-
limiting	or	resolved	with	medical	treatment.	Grade	3	events	
(13%,	3	of	23	events;	3	of	10	patients)	were	all	anemia,	which	
was	well	controlled	by	transfusion.	A	total	of	6	patients	(grade	
2,	n=3	and	grade	3,	n=3)	were	anemic	perioperatively.	The	
anemia	was	due	to	surgical	complications,	rather	than	IP	
chemotherapy,	as	4	patients	were	given	transfusion	intraop-
eratively	and	2	developed	anemia	between	postoperative	day	
1	and	4.	Most	hematologic	complication	after	chemotherapy	
occurs	7-10	days	later	and	there	was	no	leucopenia	or	throm-
bocytopenia	observed	in	this	study.	No	patient	required	reop-
eration	or	admission	to	the	intensive	care	unit,	and	no	mortal-
ity	was	observed	in	the	present	study.	
Recently,	several	studies	including	Armstrong	et	al.	[4],	Mark-
man	et	al.	[8],	and	the	National	Cancer	Institute	(USA)	[9],	an-
nounced	the	survival	benefit	of	IP	chemotherapy;	however,	
this	procedure	has	3	main	complications:	problems	related	to	
the	access	device,	abdominal	pain	with	infusion,	and	intoler-
ance	to	the	higher	doses	of	cisplatin	[10,11].	In	the	GOG	172	
study,	the	authors	observed	catheter-related	complications	
in	39	of	119	patients	(33%)	[12],	of	which	21	were	due	to	
catheter	infection.	Our	study	did	not	use	infusing	catheters;	
therefore,	there	were	no	complications	related	to	the	access	
device.	In	conventional	IP	chemotherapy,	the	cytotoxic	drug	
is	infused	in	2	L	of	fluid	to	reach	tumor	lesion	easily	in	ab-
dominal	cavity;	therefore,	patients	experience	gastrointestinal	
complications	such	as	abdominal	discomfort	or	pain,	nausea,	
vomiting,	bowel	perforation,	infection,	or	ileus.	Armstrong	et	
al.	[4]	reported	gastrointestinal	events	in	46%	of	patients	and	
Yan	et	al.	[7]	reported	nausea/vomiting	(grade	2,	n=4,	grade	3,	
n=3	in	23	patients)	and	intrabdominal	infection	(grade	3,	10%,	
grade	4,	24%).	In	our	study,	there	was	no	severe	abdominal	
pain	and	all	gastrointestinal	toxicities	were	grade	1	or	2.	This	
may	be	because	we	infused	cisplatin	with	a	smaller	volume	of	
normal	saline	(1	L)	and	contained	the	chemoagent	for	a	rela-
tively	short	time	(24	hours)	in	the	abdominal	cavity.	
The	morbidity	of	this	study	was	no	more	serious	than	HIPEC	
with	cytoreductive	surgery	studies.	In	a	review	article	of	15	
studies,	the	morbidity	was	21.3-60%,	including	significant	
complication,	while	mortality	was	up	to	10%	[6].	Another	re-
view	article	analyzed	morbidity	of	45-60%,	including	minor	
complications,	and	a	mortality	of	3.3-10%	[3].	The	studies	
show	significant	morbidity	such	as	complications	requiring	
return	to	the	surgical	intensive	care	unit,	an	invasive	proce-
dure,	or	return	to	the	operating	room.	Such	events	and	mor-
tality	were	not	observed	in	this	study.	In	a	recent	prospective	
phase	II	study,	Lim	et	al.	[13]	reported	107	adverse	events	in	
30	patients	(grade	I,	40	events;	grade	2,	46	events;	grade	3,	
21	events).	Grade	3	events	included	anemia	(5	of	21	grade	3	
events),	pleural	effusion	(4	of	21),	wound	infection	(3	of	21),	
pneumothorax	(3	of	21),	etc.	Though	the	IP	chemotherapy	im-
mediately	after	cytoreductive	surgery	designed	in	our	study	
could	not	provide	patients	with	the	benefit	of	the	heating	
effect	on	the	chemotherapeutics	like	HIPEC,	this	procedure	is	
simple,	easily	reproducible	without	any	additional	equipment	
and	operation	time,	inexpensive,	and	there	is	less	exposure	of	
the	medical	team	to	cytotoxic	chemoagents.	
In	a	review	article	of	16	studies	on	HIPEC	with	cytoreduc-
tive	surgery	in	ovarian	cancer,	Dovern	et	al.	[14]	reported	that	
survival	data	ranged	from	10.0	to	57.1	months	(disease-free	
survival)	and	from	19.0	to	76.1	months	(overall	survival).	In	ad-
dition,	Chua	et	al.	[15]	reported	that	overall	median	survival	
ranged	from	22	to	64	months,	with	median	disease-free	sur-
vival	ranging	from	10	to	57	months.	The	present	study	was	
performed	from	April	2008	and	the	survival	data	is	not	yet	
complete.	No	mortality	was	observed	during	the	follow-up	
period.	One	patient	had	liver	metastasis	16	months	postoper-
atively.	The	other	9	patients	have	been	well	controlled	by	che-
motherapy	and	observed	with	a	median	survival	of	16	months	Myung Joo Kim, et al.
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(range,	4	to	39	months)	and	the	progression	free	survival	of	13	
months	(range,	4	to	22	months).
Our	institution	is	a	secondary	care	hospital	specializing	in	
obstetrics	and	gynecology.	For	this	reason,	the	present	study	
has	several	limitations.	First,	the	proportion	of	early	stage	
disease	is	relatively	high;	6	of	the	10	enrolled	patients	were	
stage	IC.	This	affects	intraoperative	or	postoperative	complica-
tion	rates.	In	conventional	IP	chemotherapy	and	HIPEC	trials	
mainly	targeted	for	patients	of	epithelial	ovarian	cancer	with	
advanced	stage,	bowel	surgery	is	often	required	(IP	30%	in	
Walker	et	al.	[12];	HIPEC	83%	in	Lim	et	al.	[13]).	As	a	result	such	
studies	reported	more	severe	morbidities	than	this	study	in	
which	no	colon	surgery	was	required.	Second,	the	sample	size	
is	small.	However,	this	simple	intraoperative	chemotherapy	
can	be	adopted	in	secondary	care	hospitals,	which	have	no	
additional	equipment	for	HIPEC	or	monitoring	team	for	con-
ventional	postoperative	IP	chemotherapy.	
In	conclusion,	intraoperative	IP	chemotherapy	with	cisplatin	
during	surgical	procedures	is	feasible	and	relatively	safe	for	
the	treatment	of	primary	epithelial	ovarian	cancer.	Morbidity	
and	toxicity	of	the	regimen	of	this	study	design	were	accept-
able.	Further	studies,	including	long	term	prospective	and	
comparative	trials,	are	needed	to	validate	the	efficacy	of	intra-
operative	IP	chemotherapy	in	epithelial	ovarian	cancer.	
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